(*R*)-2-(7-Fluoro-4-(4-methylthiophen-2-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(7-Fluoro-3-oxo-4-(thiophen-3-yl)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(7-Fluoro-4-(5-methylthiophen-2-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(2-aminothiazol-5-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*R*)-2-(7-Fluoro-4-(furan-2-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(7-Fluoro-4-(furan-3-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(7-Fluoro-4-(5-methylfuran-2-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(4-(5-Cyanothiophen-2-yl)-7-fluoro-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(4-(4-Cyanothiophen-2-yl)-7-fluoro-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(7-Fluoro-3-oxo-4-(thiazol-5-yl)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(7-Fluoro-4-(isothiazol-5-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;


6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-1,1-dimethyl-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1*H*-pyrazol-3-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(2-methylthiazol-5-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-7-fluoro-4-(5-methylthiophen-2-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-1-methyl-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;




[0218] To trifluoroacetic acid (2 mL, 26.0 mmol) was added ethyl 1-(2,4-dimethoxybenzyl)-6-((1,3-dioxoisoindolin-2-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (198.9 mg, 0.403 mmol) at 0°C. The mixture was stirred at 0°C for 1 h, then at RT for 6 h. The mixture was concentrated under reduced pressure, and the residue was washed with IPE (5 mL) to give the title compound (183.3 mg). ^{1}H NMR (400 MHz, $CDCl_3$) δ ppm 1.42 (t, *J*=7.2Hz, 3H), 4.45 (q, *J*=7.2Hz, 2H), 4.98 (s, 2H), 7.78 - 7.81 (m, 2H), 7.91 - 7.93 (m, 2H), 8.19 (br s, 1H), 8.96 (br s, 1H).

[0219] D. Ethyl 2,4-dichloro-6-((1,3-dioxoisoindolin-2-yl)methyl)pyrimidine-5-carboxylate

[0220] A mixture of ethyl 6-((1,3-dioxoisoindolin-2-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (96.1 mg, 0.280 mmol) and phosphorus oxychloride (1 mL, 10.92 mmol) was stirred at 100°C for 12 h and allowed to cool. The mixture was concentrated under reduced pressure to remove excess $POCl_3$. The residue was treated with saturated aq $NaHCO_3$ and extracted with EtOAc. The organic phase was washed with saturated aqueous $NaHCO_3$, water, and brine, was dried over anhydrous Na_2SO_4, and then filtered through SiO_2. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography (SiO_2, hexanes/EtOAc=4/1) to give the title compound (46.0 mg, 43%). ^{1}H NMR (400 MHz, $CDCl_3$) δ ppm 1.42 (t, *J*=7.2Hz, 3H), 4.45 (q, *J*=7.2Hz, 2H), 5.05 (s, 2H), 7.76 - 7.80 (m, 2H), 7.89 - 7.93 (m, 2H).


[0221] EXAMPLE 8: 2-((1*R*,2S)-2-Aminocyclohexylamino)-4-(*m*-tolylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one (free base)




[0228] D. 2-((1*R*,2S)-2-Aminocyclohexylamino)-4-(*m*-tolylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one

[0229] To a solution of *tert*-butyl (1*S*,2*R*)-2-(5-oxo-4-(*m*-tolylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-2-ylamino)cyclohexylcarbamate (50.4 mg, 0.111 mmol) in HOAc (2 mL) was added hydrochloric acid (0.5 mL, 16.46 mmol). The mixture was stirred at RT for 30 min and then concentrated under reduced pressure. The residue was treated with saturated aq $NaHCO_3$ and extracted with EtOAc. The organic layers were washed with saturated aq $NaHCO_3$, water, and brine, were dried over anhydrous Na_2SO_4, and then filtered. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography (SiO_2, EtOAc/MeOH=20/1) to give the title compound as a white powder (11.3 mg, 29%). ^{1}H NMR (400 MHz, $CDCl_3$) δ ppm 1.48 - 1.80 (m, 10H), 2.37 (s, 3H), 3.24 (br s, 1H), 4.07 (br s, 1H), 4.20 (s, 2H), 5.55 (br s, 1H), 5.89 (br s, 1H), 6.89 - 6.91 (m, 1H), 7.22 - 7.24 (m, 1H), 7.53 - 7.63 (m, 2H), 8.49 (br s, 1H). [M+H] calc'd for $C_{19}H_{25}N_6O$, 353; found, 353.


[0230] PREPARATION 4: Methyl 2,4-dichloro-6-(*m*-tolylamino)pyrimidine-5-carboxylate




[0231] A. 2,4,6-Trichloropyrimidine-5-carboxylic acid



[0232] To a solution of diisopropylamine (23.42 mL, 164 mmol) in THF (200 mL) was slowly added butyllithium (100 mL, 160 mmol) at -78°C. The mixture was stirred at -78°C for 15 min. To this mixture was slowly added a solution of 2,4,6-trichloropyrimidine (20.06 g, 109 mmol) in THF (50 mL) at -78°C. The mixture was stirred for 1 h. Dry ice was added and the mixture was stirred at RT for 1 h. To the mixture was added 1N HCl, which was subsequently extracted with EtOAc. The organic layers were basified with




[0306] A. Methyl 6-chloro-4-cyano-2-(4-fluoro-3-methylphenylamino)nicotinate



[0307] A solution of methyl 2,6-dichloro-4-cyanonicotinate (500 mg, 2.164 mmol), 4-fluoro-3-methylaniline (325 mg, 2.60 mmol) and Et_3N (0.452 mL, 3.25 mmol) in ACN (5 mL) was stirred at 50°C for 24 h. Water and EtOAc were added to the mixture and the aqueous phase was extracted with EtOAc. The organic phases were combined, washed with H_2O and brine, dried over $MgSO_4$, and evaporated. The residue was purified by chromatography on SiO_2 to give the title compound, which contains some starting material and was used without further purification (390 mg). [M+H] calc'd for $C_{15}H_{11}ClFN_3O_2$, 320; found, 320.

[0308] B. Methyl 6-((1*R*,2*S*)-2-(*tert*-butoxycarbonylamino)cyclohexylamino)-4-cyano-2-(4-fluoro-3-methylphenylamino)nicotinate




[0309] A mixture of methyl 6-chloro-4-cyano-2-(4-fluoro-3-methylphenylamino)nicotinate (390 mg, 1.220 mmol), Et_3N (0.204 mL, 1.464 mmol) and *tert*-butyl (1*S*,2*R*)-2-aminocyclohexylcarbamate (392 mg, 1.830 mmol) in THF (5 mL)

[0543] EXAMPLE 60: 6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1-ethyl-1*H*-pyrazol-4-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one



[0544] A. *tert*-Butyl (1*S*,2*R*)-2-(4-(1-ethyl-1*H*-pyrazol-4-yl)-7-fluoro-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)cyclohexylcarbamate



[0545] A solution of *tert*-Butyl (1*S*,2*R*)-2-(4-(1-ethyl-1*H*-pyrazol-4-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)cyclohexylcarbamate (69.7mg, 0.158 mmol) in DCM (5 mL) was cooled to 0°C. SELECTFLUOR® (84 mg, 0.237 mmol) was added. The mixture was left stirring in an ice bath and was allowed to warm slowly to RT with stirring overnight. Additional SELECTFLUOR® (2 eq) was added and the reaction was stopped after 2 h. After removal of solvent, the residue was diluted with EtOAc (10 mL) and washed with saturated aq $NaHCO_3$ (5 mL), water (5 mL), and brine (5 mL). The organic layers were combined, dried over Na_2SO_4, and concentrated to a brown residue. The resulting crude material was reconstituted in MeOH/DCM (6 mL) and was purified via preparative HPLC. The fractions were collected and ACN was removed via rotary evaporation. The resulting aq solution was neutralized with saturated aq $NaHCO_3$, washed with EtOAc (2 x 200 mL), dried over Na_2SO_4, and filtered. The organic phase was stripped to dryness via rotary evaporation to yield the title compound (20 mg, 28%).[M+H] calc'd for $C_{23}H_{31}FN_6O_3$, 459; found, 459.

[0546] B. 6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1-ethyl-1*H*-pyrazol-4-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one

[0547] To a solution of *tert*-butyl (1*S*,2*R*)-2-(4-(1-ethyl-1*H*-pyrazol-4-yl)-7-fluoro-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)cyclohexylcarbamate (20 mg, 0.044

NMR (400 MHz, DMSO-d_6) δ ppm 0.79 - 0.97 (m, 6 H), 1.52 - 1.87 (m, 3 H), 4.38 (s, 2 H), 4.66 - 4.85 (m, 1 H), 6.61 (dd, *J*=3.54, 1.77 Hz, 1 H), 6.92 - 7.07 (m, 2 H), 7.36 (br s, 1 H), 7.79 (dd, *J*=1.64, 0.63 Hz, 1 H), 8.04 (dd, *J*=3.54, 0.51 Hz, 1 H), 8.32 (s, 1 H). [M+H] calc'd for $C_{17}H_{19}FN_4O_3$, 347; found, 347.

[0832] EXAMPLE 114: (*R*)-2-(7-Fluoro-4-(furan-3-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide



[0833] The title compound was prepared in a manner similar to EXAMPLE 70 using 2-(furan-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane in place of 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-pyrazole. ^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 0.80 - 0.99 (m, 6 H), 1.21 - 1.33 (m, 1 H), 1.50 - 1.60 (m, 1 H), 1.74 - 1.81 (m, 1 H), 4.38 (s, 2 H), 4.47 - 4.61 (m, 1 H), 6.89 - 6.98 (m, 1 H), 7.03 (d, *J*=7.81 Hz, 1 H), 7.35 (s, 1 H), 7.42 (s, 1 H), 7.68 (s, 1 H), 8.35 (s, 1 H), 8.98 (s, 1 H). [M+H] calc'd for $C_{17}H_{19}FN_4O_3$, 347; found, 347.


[0834] EXAMPLE 115: (*R*)-2-(7-Fluoro-4-(5-methylfuran-2-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide



[0835] The title compound was prepared in a manner similar to EXAMPLE 113 using tributyl(5-methylfuran-2-yl)stannane in place of tributyl(furan-2-yl)stannane. ^{1}H NMR (400 MHz, DMSO-d_6) δ ppm 0.84 - 0.97 (m, 6 H), 1.51 - 1.78 (m, 3 H), 2.29 - 2.36 (m, 3 H), 4.36 (s, 2 H), 4.64 - 4.86 (m, 1 H), 6.22 (dd, *J*=3.28, 1.01 Hz, 1 H), 6.92 (d, *J*=8.08 Hz, 1 H), 7.01 (br s, 1 H), 7.41 (br s, 1 H), 7.97 (d, *J*=3.03 Hz, 1 H), 8.26 (s, 1 H). [M+H] calc'd for $C_{18}H_{21}FN_4O_3$, 361; found, 361.

WHAT IS CLAIMED IS:

1. A compound of Formula 1,



1

,

or a pharmaceutically acceptable salt thereof, wherein:

G is $C(R^5)$;

L^1 and L^2 are each independently selected from -NH- and a bond;

R^1 and R^2 are each independently selected from hydrogen, halo, C_{1-3} alkyl, and C_{1-3} haloalkyl, or R^1 and R^2, together with the atom to which they are attached, form a C_{3-6} cycloalkyl;

R^3 is selected from C_{2-6} alkyl, C_{3-8} cycloalkyl, C_{2-5} heterocyclyl, and C_{1-9} heteroaryl, each optionally substituted with from one to five substituents independently selected from halo, oxo, $-NO_2$, -CN, R^6, and R^7;

R^4 is selected from C_{3-8} cycloalkyl, C_{2-5} heterocyclyl, C_{6-14} aryl, and C_{1-9} heteroaryl, each optionally substituted with from one to five substituents independently selected from halo, oxo, -CN, R^6, and R^7;

R^5 is selected from hydrogen, halo, -CN, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{2-5} heterocyclyl, C_{1-5} heteroaryl, and R^{10}, wherein the alkyl, alkenyl, alkynyl moieties are each optionally substituted with from one to five substituents independently selected from halo, -CN, oxo, and R^{10}, and wherein the heterocyclyl moiety has 3 to 6 ring atoms and the heteroaryl moiety has 5 or 6 ring atoms, and the heterocyclyl and heteroaryl moieties are each optionally substituted with from one to four substituents independently selected from halo, $-NO_2$, -CN, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} haloalkyl, and R^{10};

each R^6 is independently selected from $-OR^8$, $-N(R^8)R^9$, $-NR^8C(O)R^9$, $-C(O)R^8$, $-C(O)OR^8$, $-C(O)N(R^8)R^9$, $-C(O)N(R^8)OR^9$, $-C(O)N(R^8)S(O)_2R^9$, $-N(R^8)S(O)_2R^9$, $-S(O)_nR^8$, and $-S(O)_2N(R^8)R^9$;

each R^7 is independently selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl-$(CH_2)_m$-, C_{6-14} aryl-$(CH_2)_m$-, C_{2-5} heterocyclyl-$(CH_2)_m$-, and

C_{1-9} heteroaryl-$(CH_2)_m$-, each optionally substituted with from one to five substituents independently selected from halo, oxo, -NO_2, -CN, C_{1-6} alkyl, C_{1-6} haloalkyl, and R^{10};

each R^8 and R^9 is independently selected from hydrogen or from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl-$(CH_2)_m$-, C_{6-14} aryl-$(CH_2)_m$-, C_{2-5} heterocyclyl-$(CH_2)_m$-, and C_{1-9} heteroaryl-$(CH_2)_m$-, each optionally substituted with from one to five substituents independently selected from halo, oxo, -NO_2, -CN, C_{1-6} alkyl, C_{1-6} haloalkyl, and R^{10};

each R^{10} is independently selected from -OR^{11}, -$N(R^{11})R^{12}$, -$N(R^{11})C(O)R^{12}$, -$C(O)R^{11}$, -$C(O)OR^{11}$, -$C(O)N(R^{11})R^{12}$, -$C(O)N(R^{11})OR^{12}$, -$C(O)N(R^{11})S(O)_2R^{12}$, -$NR^{11}S(O)_2R^{12}$, -$S(O)_nR^{11}$, and -$S(O)_2N(R^{11})R^{12}$;

each R^{11} and R^{12} is independently selected from hydrogen and C_{1-6} alkyl;

each n is independently selected from 0, 1 and 2; and

each m is independently selected from 0, 1, 2, 3, and 4;

wherein each of the aforementioned heteroaryl moieties has one to four heteroatoms independently selected from N, O, and S, and each of the aforementioned heterocyclyl moieties is saturated or partially unsaturated and has one or two heteroatoms independently selected from N, O, and S.

2. A compound or pharmaceutically acceptable salt according to claim 1, wherein L^1 is -NH-.

3. A compound or pharmaceutically acceptable salt according to claim 1, wherein L^2 is a bond.

4. A compound or pharmaceutically acceptable salt according to claim 1, wherein R^1 and R^2 are both hydrogen.

5. (Currently amended) A compound or pharmaceutically acceptable salt according to claim 1, wherein R^3 is C_{3-8} cycloalkyl, optionally substituted with from one to five substituents independently selected from halo, oxo, -NO_2, -CN, R^6, and R^7.

6. A compound or pharmaceutically acceptable salt according to claim 5, wherein R^3 is 2-amino-cyclohex-1-yl optionally substituted with from one to four substituents independently selected from halo, oxo, -NO_2, -CN, R^6, and R^7.

7. A compound or pharmaceutically acceptable salt according to claim 1, wherein R^3 is C_{2-5} heterocyclyl optionally substituted with from one to five substituents independently selected from halo, oxo, $-NO_2$, -CN, R^6, and R^7.

8. A compound or pharmaceutically acceptable salt according to claim 7, wherein R^3 is 3-aminotetrahydro-2*H*-pyran-4-yl optionally substituted with from one to four substituents independently selected from halo, oxo, $-NO_2$, -CN, R^6, and R^7.

9. A compound or pharmaceutically acceptable salt according to claim 1, wherein R^4 is C_{1-9} heteroaryl optionally substituted with from one to five substituents independently selected from halo, oxo, -CN, R^6, and R^7.

10. A compound or pharmaceutically acceptable salt according to claim 9, wherein R^4 is a monocyclic C_{2-4} heteroaryl optionally substituted with from one to four substituents independently selected from halo, -CN, R^6, and R^7.

11. A compound or pharmaceutically acceptable salt according to claim 10, wherein R^4 is selected from pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazolyl, and thiazolyl, each optionally substituted with from one to three substituents independently selected from halo, -CN, R^6, and R^7.

12. A compound or pharmaceutically acceptable salt according to claim 11, wherein R^4 is selected from thienyl, pyrazolyl, isothiazolyl, and thiazolyl, each optionally substituted with from one to three substituents independently selected from halo, -CN, R^6, and R^7.

13. A compound or pharmaceutically acceptable salt according to claim 12, wherein R^4 is pyrazolyl optionally substituted with from one to three substituents independently selected from halo, -CN, R^6, and R^7.

14. A compound or pharmaceutically acceptable salt according to claim 13, wherein R^4 is pyrazol-4-yl optionally substituted with from one to three substituents independently selected from halo, -CN, R^6, and R^7.

15. A compound or pharmaceutically acceptable salt according to claim 9, wherein R^4 is substituted with methyl, ethyl, cyclopropyl or C_{1-2} haloalkyl.

16. A compound or pharmaceutically acceptable salt according to claim 1, wherein R^5 is selected from hydrogen and halo.

17. A compound or pharmaceutically acceptable salt according to claim 16, wherein R^5 is selected from chloro and fluoro.

18. A compound according to claim 1, which is selected from the following compounds:

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

4-(1*H*-Indazol-6-ylamino)-6-((1*R*,2*S*)-2-aminocyclohexylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(4-fluoro-3-methylphenylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-chloro-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(pyrazolo[1,5-*a*]pyridin-3-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(3-(methylsulfonyl)phenylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclopentylamino)-4-(3-(methylsulfonyl)phenylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*R*)-4-Methyl-2-(4-(3-(methylsulfonyl)phenylamino)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)pentanamide;

(*R*)-4-Methyl-2-(4-(1-methyl-1*H*-pyrazol-4-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)pentanamide;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(benzofuran-3-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-aminocyclohexylamino)-7-fluoro-4-(imidazo[1,2-*a*]pyridin-3-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-aminocyclohexylamino)-4-(benzo[*b*]thiophen-3-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*S*,2*R*)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(*2H*)-one;

(*R*)-6-(2-Amino-3-ethoxypropylamino)-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*R*)-6-(2-Amino-3-ethoxypropylamino)-7-fluoro-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-(2-Amino-3,3,3-trifluoropropylamino)-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*R*)-4-Methyl-2-(3-oxo-4-(*m*-tolylamino)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)pentanamide;

6-(*cis*-4-Aminotetrahydrofuran-3-ylamino)-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2H)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1-ethyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1-ethyl-1*H*-pyrazol-4-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1-cyclopropyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1-(difluoromethyl)-1*H*-pyrazol-4-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1-cyclopropyl-1*H*-pyrazol-4-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

cis-6-(2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-7-fluoro-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-(*cis*-2-Amino-4,4-difluorocyclopentylamino)-7-fluoro-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-c]pyridin-3(2*H*)-one;

6-(*cis*-2-Amino-3,3-difluorocyclohexylamino)-7-fluoro-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-(*cis*-2-Amino-3,3-difluorocyclohexylamino)-4-(1-(difluoromethyl)-1*H*-pyrazol-4-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-(*cis*-2-amino-3,3-difluorocyclohexylamino)-4-(1-cyclopropyl-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;

(*R*)-2-(7-Fluoro-4-(1-methyl-1*H*-pyrazol-4-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(4-(1-(Difluoromethyl)-1*H*-pyrazol-4-yl)-7-fluoro-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(4-(1-Cyclopropyl-1*H*-pyrazol-4-yl)-7-fluoro-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(4-(Benzofuran-3-yl)-7-fluoro-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(7-Fluoro-3-oxo-4-(pyrazolo[1,5-*a*]pyridin-3-yl)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-chloro-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-3-oxo-4-(*m*-tolylamino)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridine-7-carbonitrile;

(*R*)-6-(2-Amino-3-methoxypropylamino)-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*R*)-6-(2-Amino-3-methoxypropylamino)-3-oxo-4-(*m*-tolylamino)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridine-7-carbonitrile;

(*R*)-6-(2-Amino-3-methoxypropylamino)-7-fluoro-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

7-Acryloyl-6-((1*R*,2*S*)-2-aminocyclohexylamino)-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-iodo-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-(1*H*-pyrazol-4-yl)-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-(*cis*-2-Amino-3,3-difluorocyclohexylamino)-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-(1-methyl-1*H*-pyrazol-5-yl)-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-4-Aminotetrahydro-2*H*-pyran-3-ylamino)-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-methyl-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-7-fluoro-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-methyl-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*R*)-6-(2-Amino-3-methoxypropylamino)-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-7-fluoro-4-(pyrazolo[1,5-*a*]pyridin-3-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-4-(1-(difluoromethyl)-1*H*-pyrazol-4-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-4-(benzofuran-3-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*S*)-6-(3-Aminopyrrolidin-1-yl)-7-fluoro-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*S*)-6-(3-Aminopiperidin-1-yl)-7-fluoro-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(1-isopropyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

7-Fluoro-4,6-bis(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-bromo-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*R*)-6-(2-Amino-3-methoxypropylamino)-7-fluoro-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-7-fluoro-4-(thiophen-3-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-7-fluoro-4-(4-methylthiophen-2-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(4-methylthiophen-2-yl)-1*H*-pyrrolo[3,4-c]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(thiophen-3-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*R*)-2-(7-Fluoro-4-(1-methyl-1*H*-pyrazol-4-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-*N*,4-dimethylpentanamide;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(5-methylthiophen-2-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*R*)-2-(7-Fluoro-4-(4-methylthiophen-2-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(7-Fluoro-3-oxo-4-(thiophen-3-yl)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(7-Fluoro-4-(5-methylthiophen-2-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(2-aminothiazol-5-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*R*)-2-(7-Fluoro-4-(furan-2-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(7-Fluoro-4-(furan-3-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(7-Fluoro-4-(5-methylfuran-2-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(4-(5-Cyanothiophen-2-yl)-7-fluoro-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(4-(4-Cyanothiophen-2-yl)-7-fluoro-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(7-Fluoro-3-oxo-4-(thiazol-5-yl)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(7-Fluoro-4-(isothiazol-5-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-1,1-dimethyl-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1*H*-pyrazol-3-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(2-methylthiazol-5-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-7-fluoro-4-(5-methylthiophen-2-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-1-methyl-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*R*)-2-(7-Fluoro-3-oxo-4-(thiophen-2-yl)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-7-fluoro-4-(thiophen-2-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-7-fluoro-4-(thiazol-5-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(thiophen-2-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-7-fluoro-4-(4-(trifluoromethyl)-1*H*-imidazol-1-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(4-methyl-1*H*-imidazol-1-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-7-fluoro-4-(3-methylisothiazol-5-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-7-fluoro-4-(2-methylthiazol-5-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*R*)-2-(7-Fluoro-4-(2-methylthiazol-5-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-4-(5-chlorothiophen-2-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-4-(1-cyclopropyl-1*H*-pyrazol-4-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

a stereoisomer of any of the aforementioned compounds; and

a pharmaceutically acceptable salt of any of the aforementioned compounds or stereoisomers.

19. A compound according to claim 1, which is 6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one or a pharmaceutically acceptable salt thereof.

20. A compound according to claim 1, which is 6-((1*S*,2*R*)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(*2H*)-one or a pharmaceutically acceptable salt thereof.

21. A compound according to claim 1, which is 6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1-(difluoromethyl)-1*H*-pyrazol-4-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one or a pharmaceutically acceptable salt thereof.

22. A compound according to claim 1, which is *cis*-6-(2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one or a pharmaceutically acceptable salt thereof.

23. A compound according to claim 1, which is 6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-4-(1-(difluoromethyl)-1*H*-pyrazol-4-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one or a pharmaceutically acceptable salt thereof.

24. A compound according to claim 1, which is 6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-7-fluoro-4-(3-methylisothiazol-5-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one or a pharmaceutically acceptable salt thereof.

25. A pharmaceutical composition comprising:

a compound or pharmaceutically acceptable salt as defined in claim 1; and

a pharmaceutically acceptable excipient.

26. A combination of an effective amount of a compound or pharmaceutically acceptable salt as defined in claim 1, and at least one additional pharmacologically active agent.

27. A combination according to claim 26, wherein the additional pharmacologically active agent is a disease-modifying antirheumatic drug (DMARD).

28. A combination according to claim 27, wherein the DMARD is methotrexate.

(*R*)-2-(7-Fluoro-4-(4-methylthiophen-2-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(7-Fluoro-3-oxo-4-(thiophen-3-yl)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(7-Fluoro-4-(5-methylthiophen-2-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(2-aminothiazol-5-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*R*)-2-(7-Fluoro-4-(furan-2-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(7-Fluoro-4-(furan-3-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(7-Fluoro-4-(furan-2-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(4-(5-Cyanothiophen-2-yl)-7-fluoro-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(4-(4-Cyanothiophen-2-yl)-7-fluoro-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(7-Fluoro-3-oxo-4-(thiazol-5-yl)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(7-Fluoro-4-(isothiazol-5-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;


6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-1,1-dimethyl-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1*H*-pyrazol-3-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(2-methylthiazol-5-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-7-fluoro-4-(5-methylthiophen-2-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-1-methyl-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;



[0218] To trifluoroacetic acid (2 mL, 26.0 mmol) was added ethyl 1-(2,4-dimethoxybenzyl)-6-((1,3-dioxoisoindolin-2-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (198.9 mg, 0.403 mmol) at 0°C. The mixture was stirred at 0°C for 1 h, then at RT for 6 h. The mixture was concentrated under reduced pressure, and the residue was washed with IPE (5 mL) to give the title compound (183.3 mg). ^{1}H NMR (400 MHz, $CDCl_3$) δ ppm 1.42 (t, *J*=7.2Hz, 3H), 4.45 (q, *J*=7.2Hz, 2H), 4.98 (s, 2H), 7.78 - 7.81 (m, 2H), 7.91 - 7.93 (m, 2H), 8.19 (br s, 1H), 8.96 (br s, 1H).

[0219] D. Ethyl 2,4-dichloro-6-((1,3-dioxoisoindolin-2-yl)methyl)pyrimidine-5-carboxylate

[0220] A mixture of ethyl 6-((1,3-dioxoisoindolin-2-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (96.1 mg, 0.280 mmol) and phosphorus oxychloride (1 mL, 10.92 mmol) was stirred at 100°C for 12 h and allowed to cool. The mixture was concentrated under reduced pressure to remove excess $POCl_3$. The residue was treated with saturated aq $NaHCO_3$ and extracted with EtOAc. The organic phase was washed with saturated aqueous $NaHCO_3$, water, and brine, was dried over anhydrous Na_2SO_4, and then filtered through SiO_2. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography (SiO_2, hexanes/EtOAc=4/1) to give the title compound (46.0 mg, 43%). ^{1}H NMR (400 MHz, $CDCl_3$) δ ppm 1.42 (t, *J*=7.2Hz, 3H), 4.45 (q, *J*=7.2Hz, 2H), 5.05 (s, 2H), 7.76 - 7.80 (m, 2H), 7.89 - 7.93 (m, 2H).


[0221] EXAMPLE 8: 2-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(3-(trifluoromethyl)phenylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one (free base)




[0228] D. 2-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(3-(trifluoromethyl)phenylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one

[0229] To a solution of *tert*-butyl (1*S*,2*R*)-2-(5-oxo-4-(*m*-tolylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-2-ylamino)cyclohexylcarbamate (50.4 mg, 0.111 mmol) in HOAc (2 mL) was added hydrochloric acid (0.5 mL, 16.46 mmol). The mixture was stirred at RT for 30 min and then concentrated under reduced pressure. The residue was treated with saturated aq $NaHCO_3$ and extracted with EtOAc. The organic layers were washed with saturated aq $NaHCO_3$, water, and brine, were dried over anhydrous Na_2SO_4, and then filtered. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography (SiO_2, EtOAc/MeOH=20/1) to give the title compound as a white powder (11.3 mg, 29%). ^1H NMR (400 MHz, $CDCl_3$) δ ppm 1.48 - 1.80 (m, 10H), 2.37 (s, 3H), 3.24 (br s, 1H), 4.07 (br s, 1H), 4.20 (s, 2H), 5.55 (br s, 1H), 5.89 (br s, 1H), 6.89 - 6.91 (m, 1H), 7.22 - 7.24 (m, 1H), 7.53 - 7.63 (m, 2H), 8.49 (br s, 1H). [M+H] calc'd for $C_{19}H_{25}N_6O$, 353; found, 353.


[0230] PREPARATION 4: Methyl 2,4-dichloro-6-(*m*-tolylamino)pyrimidine-5-carboxylate




[0231] A. 2,4,6-Trichloropyrimidine-5-carboxylic acid



[0232] To a solution of diisopropylamine (23.42 mL, 164 mmol) in THF (200 mL) was slowly added butyllithium (100 mL, 160 mmol) at -78°C. The mixture was stirred at -78°C for 15 min. To this mixture was slowly added a solution of 2,4,6-trichloropyrimidine (20.06 g, 109 mmol) in THF (50 mL) at -78°C. The mixture was stirred for 1 h. Dry ice was added and the mixture was stirred at RT for 1 h. To the mixture was added 1N HCl, which was subsequently extracted with EtOAc. The organic layers were basified with




[0306] A. Methyl 6-chloro-4-cyano-2-(4-fluoro-3-ethylphenylamino)nicotinate



[0307] A solution of methyl 2,6-dichloro-4-cyanonicotinate (500 mg, 2.164 mmol), 4-fluoro-3-methylaniline (325 mg, 2.60 mmol) and Et_3N (0.452 mL, 3.25 mmol) in ACN (5 mL) was stirred at 50°C for 24 h. Water and EtOAc were added to the mixture and the aqueous phase was extracted with EtOAc. The organic phases were combined, washed with H_2O and brine, dried over $MgSO_4$, and evaporated. The residue was purified by chromatography on SiO_2 to give the title compound, which contains some starting material and was used without further purification (390 mg). [M+H] calc'd for $C_{15}H_{11}ClFN_3O_2$, 320; found, 320.

[0308] B. Methyl 6-((1*R*,2*S*)-2-(*tert*-butoxycarbonylamino)cyclohexylamino)-4-cyano-2-(4-fluoro-3-methylphenylamino)nicotinate




[0309] A mixture of methyl 6-chloro-4-cyano-2-(4-fluoro-3-methylphenylamino)nicotinate (390 mg, 1.220 mmol), Et_3N (0.204 mL, 1.464 mmol) and *tert*-butyl (1*S*,2*R*)-2-aminocyclohexylcarbamate (392 mg, 1.830 mmol) in THF (5 mL)

[0543] EXAMPLE 60: 6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1-ethyl-1*H*-pyrazol-4-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one



[0544] A. *tert*-Butyl (1*S*,2*R*)-2-(4-(1-ethyl-1*H*-pyrazol-4-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino



[0545] A solution of *tert*-Butyl (1*S*,2*R*)-2-(4-(1-ethyl-1*H*-pyrazol-4-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)cyclohexylcarbamate (69.7mg, 0.158 mmol) in DCM (5 mL) was cooled to 0°C. SELECTFLUOR® (84 mg, 0.237 mmol) was added. The mixture was left stirring in an ice bath and was allowed to warm slowly to RT with stirring overnight. Additional SELECTFLUOR® (2 eq) was added and the reaction was stopped after 2 h. After removal of solvent, the residue was diluted with EtOAc (10 mL) and washed with saturated aq $NaHCO_3$ (5 mL), water (5 mL), and brine (5 mL). The organic layers were combined, dried over Na_2SO_4, and concentrated to a brown residue. The resulting crude material was reconstituted in MeOH/DCM (6 mL) and was purified via preparative HPLC. The fractions were collected and ACN was removed via rotary evaporation. The resulting aq solution was neutralized with saturated aq $NaHCO_3$, washed with EtOAc (2 x 200 mL), dried over Na_2SO_4, and filtered. The organic phase was stripped to dryness via rotary evaporation to yield the title compound (20 mg, 28%).[M+H] calc'd for $C_{23}H_{31}FN_6O_3$, 459; found, 459.

[0546] B. 6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1-ethyl-1*H*-pyrazol-4-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one

[0547] To a solution of *tert*-butyl (1*S*,2*R*)-2-(4-(1-ethyl-1*H*-pyrazol-4-yl)-7-fluoro-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)cyclohexylcarbamate (20 mg, 0.044


NMR (400 MHz, DMSO-d_6) δ ppm 0.79 - 0.97 (m, 6 H), 1.52 - 1.87 (m, 3 H), 4.38 (s, 2 H), 4.66 - 4.85 (m, 1 H), 6.61 (dd, *J*=3.54, 1.77 Hz, 1 H), 6.92 - 7.07 (m, 2 H), 7.36 (br s, 1 H), 7.79 (dd, *J*=1.64, 0.63 Hz, 1 H), 8.04 (dd, *J*=3.54, 0.51 Hz, 1 H), 8.32 (s, 1 H). [M+H] calc'd for $C_{17}H_{19}FN_4O_3$, 347; found, 347.

[0832] EXAMPLE 114: (*R*)-2-(7-Fluoro-4-(furan-3-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide



[0833] The title compound was prepared in a manner similar to EXAMPLE 70 using 2-(furan-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane in place of 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-pyrazole. ^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 0.80 - 0.99 (m, 6 H), 1.21 - 1.33 (m, 1 H), 1.50 - 1.60 (m, 1 H), 1.74 - 1.81 (m, 1 H), 4.38 (s, 2 H), 4.47 - 4.61 (m, 1 H), 6.89 - 6.98 (m, 1 H), 7.03 (d, *J*=7.81 Hz, 1 H), 7.35 (s, 1 H), 7.42 (s, 1 H), 7.68 (s, 1 H), 8.35 (s, 1 H), 8.98 (s, 1 H). [M+H] calc'd for $C_{17}H_{19}FN_4O_3$, 347; found, 347.


[0834] EXAMPLE 115: (*R*)-2-(7-Fluoro-4-(furan-2-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide



[0835] The title compound was prepared in a manner similar to EXAMPLE 113 using tributyl(5-methylfuran-2-yl)stannane *tert*-butyl in place of tributyl(furan-2-yl)stannane. ^{1}H NMR (400 MHz, DMSO-d_6) δ ppm 0.84 - 0.97 (m, 6 H), 1.51 - 1.78 (m, 3 H), 2.29 - 2.36 (m, 3 H), 4.36 (s, 2 H), 4.64 - 4.86 (m, 1 H), 6.22 (dd, *J*=3.28, 1.01 Hz, 1 H), 6.92 (d, *J*=8.08 Hz, 1 H), 7.01 (br s, 1 H), 7.41 (br s, 1 H), 7.97 (d, *J*=3.03 Hz, 1 H), 8.26 (s, 1 H). [M+H] calc'd for $C_{18}H_{21}FN_4O_3$, 361; found, 361.

WHAT IS CLAIMED IS:

1. A compound of Formula 1,



1 ,

or a pharmaceutically acceptable salt thereof, wherein:

G is selected from N and $C(R^5)$;

L^1 and L^2 are each independently selected from -NH- and a bond;

R^1 and R^2 are each independently selected from hydrogen, halo, C_{1-3} alkyl, and C_{1-3} haloalkyl, or R^1 and R^2, together with the atom to which they are attached, form a C_{3-6} cycloalkyl;

R^3 is selected from C_{2-6} alkyl, C_{3-8} cycloalkyl, C_{2-5} heterocyclyl, and C_{1-9} heteroaryl, each optionally substituted with from one to five substituents independently selected from halo, oxo, $-NO_2$, -CN, R^6, and R^7;

R^4 is selected from C_{3-8} cycloalkyl, C_{2-5} heterocyclyl, C_{6-14} aryl, and C_{1-9} heteroaryl, each optionally substituted with from one to five substituents independently selected from halo, oxo, -CN, R^6, and R^7;

R^5 is selected from hydrogen, halo, -CN, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{2-5} heterocyclyl, C_{1-5} heteroaryl, and R^{10}, wherein the alkyl, alkenyl, alkynyl moieties are each optionally substituted with from one to five substituents independently selected from halo, -CN, oxo, and R^{10}, and wherein the heterocyclyl moiety has 3 to 6 ring atoms and the heteroaryl moiety has 5 or 6 ring atoms, and the heterocyclyl and heteroaryl moieties are each optionally substituted with from one to four substituents independently selected from halo, $-NO_2$, -CN, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} haloalkyl, and R^{10};

each R^6 is independently selected from $-OR^8$, $-N(R^8)R^9$, $-NR^8C(O)R^9$, $-C(O)R^8$, $-C(O)OR^8$, $-C(O)N(R^8)R^9$, $-C(O)N(R^8)OR^9$, $-C(O)N(R^8)S(O)_2R^9$, $-N(R^8)S(O)_2R^9$, $-S(O)_nR^8$, and $-S(O)_2N(R^8)R^9$;

each R^7 is independently selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl-$(CH_2)_m$-, C_{6-14} aryl-$(CH_2)_m$-, C_{2-5} heterocyclyl-$(CH_2)_m$-, and C_{1-9} heteroaryl-$(CH_2)_m$-, each optionally substituted with from one to five substituents independently selected from halo, oxo, $-NO_2$, -CN, C_{1-6} alkyl, C_{1-6} haloalkyl, and R^{10};

each R^8 and R^9 is independently selected from hydrogen or from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl-$(CH_2)_m$-, C_{6-14} aryl-$(CH_2)_m$-, C_{2-5} heterocyclyl-$(CH_2)_m$-, and C_{1-9} heteroaryl-$(CH_2)_m$-, each optionally substituted with from one to five substituents independently selected from halo, oxo, $-NO_2$, -CN, C_{1-6} alkyl, C_{1-6} haloalkyl, and R^{10};

each R^{10} is independently selected from $-OR^{11}$, $-N(R^{11})R^{12}$, $-N(R^{11})C(O)R^{12}$, $-C(O)R^{11}$, $-C(O)OR^{11}$, $-C(O)N(R^{11})R^{12}$, $-C(O)N(R^{11})OR^{12}$, $-C(O)N(R^{11})S(O)_2R^{12}$, $-NR^{11}S(O)_2R^{12}$, $-S(O)_nR^{11}$, and $-S(O)_2N(R^{11})R^{12}$;

each R^{11} and R^{12} is independently selected from hydrogen and C_{1-6} alkyl;

each n is independently selected from 0, 1 and 2; and

each m is independently selected from 0, 1, 2, 3, and 4;

wherein each of the aforementioned heteroaryl moieties has one to four heteroatoms independently selected from N, O, and S, and each of the aforementioned heterocyclyl moieties is saturated or partially unsaturated and has one or two heteroatoms independently selected from N, O, and S.

2. A compound or pharmaceutically acceptable salt according to claim 1, wherein L^1 is -NH-.

3. A compound or pharmaceutically acceptable salt according to claim 1, wherein L^1 is a bond.

4. A compound or pharmaceutically acceptable salt according to any one of the preceding claims, wherein L^2 is -NH-.

5. A compound or pharmaceutically acceptable salt according to any one of claims 1 to 3, wherein L^2 is a bond.

6. A compound or pharmaceutically acceptable salt according to any one of the preceding claims, wherein G is N.

7. A compound or pharmaceutically acceptable salt according to any one of claims 1 to 5, wherein G is $C(R^5)$.

8. A compound or pharmaceutically acceptable salt according to any one of the preceding claims, wherein R^1 and R^2 are both hydrogen.

9. A compound or pharmaceutically acceptable salt according to any one of the preceding claims, wherein R^3 is C_{3-8} cycloalkyl, optionally substituted with from one to five substituents independently selected from halo, oxo, $-NO_2$, -CN, R^6, and R^7.

10. A compound or pharmaceutically acceptable salt according to claim 9, wherein R^3 is 2-amino-C_{3-8} cycloalk-1-yl, optionally substituted with from one to four substituents independently selected from halo, oxo, $-NO_2$, -CN, R^6, and R^7.

11. A compound or pharmaceutically acceptable salt according to claim 10, wherein R^3 is 2-amino-cyclohex-1-yl optionally substituted with from one to four substituents independently selected from halo, oxo, $-NO_2$, -CN, R^6, and R^7.

12. A compound or pharmaceutically acceptable salt according to any one of claims 1 to 8, wherein R^3 is C_{2-6} alkyl optionally substituted with from one to five substituents independently selected from halo, oxo, $-NO_2$, -CN, R^6, and R^7.

13. A compound or pharmaceutically acceptable salt according to claim 12, wherein R^3 is 2-amino-C_{2-6} alk-1-yl optionally substituted with from one to four substituents independently selected from halo, oxo, $-NO_2$, -CN, R^6, and R^7.

14. A compound or pharmaceutically acceptable salt according to claim 13, wherein R^3 is 2-aminoethan-1-yl optionally substituted with from one to four substituents independently selected from halo, oxo, $-NO_2$, -CN, R^6, and R^7.

15. A compound or pharmaceutically acceptable salt according to claim 14, wherein R^3 is 2-amino-2-oxoethan-1-yl optionally substituted with one or two substituents independently selected from halo, oxo, $-NO_2$, -CN, R^6, and R^7.

16. A compound or pharmaceutically acceptable salt according to any one of claims 1 to 8, wherein R^3 is C_{2-5} heterocyclyl optionally substituted with from one to five substituents independently selected from halo, oxo, $-NO_2$, -CN, R^6, and R^7.

17. A compound or pharmaceutically acceptable salt according to claim 16, wherein R^3 is C_{2-5} heterocyclyl substituted with an amino and optionally substituted with from one to four additional substituents independently selected from halo, oxo, $-NO_2$, -CN, R^6, and R^7.

18. A compound or pharmaceutically acceptable salt according to claim 17, wherein R^3 is 3-aminotetrahydro-2*H*-pyran-4-yl optionally substituted with from one to four substituents independently selected from halo, oxo, $-NO_2$, -CN, R^6, and R^7.

19. A compound or pharmaceutically acceptable salt according to any one of claims 1 and 3 to 8, wherein R^3 is C_{2-5} heterocyclyl or an amino-substituted C_{2-5} heterocyclyl, each optionally substituted with from one to five or from one to four substituents, respectively, independently selected from halo, oxo, $-NO_2$, -CN, R^6, and R^7, wherein one of the heteroatoms of the heterocyclyl moiety is directly attached to L^1, and L^1 is a bond.

20. A compound or pharmaceutically acceptable salt according to any one of the preceding claims, wherein R^4 is selected from C_{6-14} aryl and C_{1-9} heteroaryl, each optionally substituted with from one to five substituents independently selected from halo, oxo, -CN, R^6, and R^7.

21. A compound or pharmaceutically acceptable salt according to any one of the preceding claims, wherein R^4 is phenyl optionally substituted with from one to five substituents independently selected from halo, -CN, R^6, and R^7.

22. A compound or pharmaceutically acceptable salt according to any one of claims 1 to 20, wherein R^4 is C_{1-9} heteroaryl optionally substituted with from one to five substituents independently selected from halo, oxo, -CN, R^6, and R^7.

23. A compound or pharmaceutically acceptable salt according to claim 22, wherein R^4 is a monocyclic C_{2-4} heteroaryl optionally substituted with from one to four substituents independently selected from halo, -CN, R^6, and R^7.

24. A compound or pharmaceutically acceptable salt according to claim 23, wherein R^4 is selected from pyrrolyl, furanyl, thiopheneyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazolyl, and thiazolyl, each optionally substituted with from one to three substituents independently selected from halo, -CN, R^6, and R^7.

25. A compound or pharmaceutically acceptable salt according to claim 24, wherein R^4 is selected from thiopheneyl, pyrazolyl, isothiazolyl, and thiazolyl, each optionally substituted with from one to three substituents independently selected from halo, -CN, R^6, and R^7.

26. A compound or pharmaceutically acceptable salt according to claim 25, wherein R^4 is pyrazolyl optionally substituted with from one to three substituents independently selected from halo, -CN, R^6, and R^7.

27. A compound or pharmaceutically acceptable salt according to claim 26, wherein R^4 is pyrazol-4-yl optionally substituted with from one to three substituents independently selected from halo, -CN, R^6, and R^7.

28. A compound or pharmaceutically acceptable salt according to any one of claims 20 to 27, wherein R^4 is substituted with methyl, ethyl, cyclopropyl or C_{1-2} haloalkyl.

29. A compound or pharmaceutically acceptable salt according to any one of claims 1 to 5 and 7 to 28, wherein R^5 is C_{1-5} heteroaryl optionally substituted with from one to four substituents independently selected from halo, $-NO_2$, -CN, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} haloalkyl, and R^{10}.

30. A compound or pharmaceutically acceptable salt according to any one of claims 1 to 5 and 7 to 28, wherein R^5 is selected from hydrogen and halo.

31. A compound or pharmaceutically acceptable salt according to claim 30, wherein R^5 is selected from chloro and fluoro.

32. A compound according to claim 1, which is selected from the following compounds:

2-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(*m*-tolylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

2-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(3-fluorophenylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

2-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(3-chlorophenylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

4-(1*H*-Indazol-6-ylamino)-2-((1*R*,2*S*)-2-aminocyclohexylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

2-((1*R*,2*S*)-2-aminocyclohexylamino)-4-(3-(trifluoromethyl)phenylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

cis-2-(2-aminocyclohexylamino)-4-(3-(trifluoromethyl)phenylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

2-(1-Methyl-1*H*-pyrazol-4-yl)-4-(*m*-tolylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

2-(4-Ethylpiperazin-1-yl)-4-(*m*-tolylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

2-(Cyclohexylamino)-4-(*m*-tolylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

cis-2-(2-Hydroxycyclohexylamino)-4-(*m*-tolylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

2-(3-Aminopiperidin-1-yl)-4-(*m*-tolylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

2-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1-methyl-1*H*-pyrazol-4-yl)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

2-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1-isobutyl-1*H*-pyrazol-4-yl)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

2-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-phenyl-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

2-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(benzo[*b*]thiophen-3-yl)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

2-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1-ethyl-1*H*-pyrazol-4-yl)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

2-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1-benzyl-1*H*-pyrazol-4-yl)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

2-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(imidazo[1,2-*a*]pyridin-3-yl)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

2-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1-propyl-1*H*-pyrazol-4-yl)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

2-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1-(2-methoxyethyl)-1*H*-pyrazol-4-yl)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

4-(1*H*-Indazol-6-ylamino)-6-((1*R*,2*S*)-2-aminocyclohexylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(4-fluoro-3-methylphenylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-chloro-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(pyrazolo[1,5-*a*]pyridin-3-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

2-(2-(Aminomethyl)piperidin-1-yl)-4-(*m*-tolylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(3-(methylsulfonyl)phenylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclopentylamino)-4-(3-(methylsulfonyl)phenylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*R*)-4-Methyl-2-(4-(3-(methylsulfonyl)phenylamino)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)pentanamide;

(*R*)-4-Methyl-2-(4-(1-methyl-1*H*-pyrazol-4-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)pentanamide;

2-((1*R*,2*S*)-2-(Dimethylamino)cyclohexylamino)-4-(*m*-tolylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

2-((1*R*,2*S*)-2-(Methylamino)cyclohexylamino)-4-(*m*-tolylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

2'-((1*R*,2*S*)-2-Aminocyclohexylamino)-4'-(*m*-tolylamino)spiro[cyclopropane-1,7'-pyrrolo[3,4-*d*]pyrimidin]-5'(6'*H*)-one;

2-(2-Aminoethylamino)-4-(*m*-tolylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

2-(2-Amino-2-methylpropylamino)-4-(*m*-tolylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

2-(5-Oxo-4-(*m*-tolylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-2-ylamino)acetamide;

2-((2-Aminoethyl)(methyl)amino)-4-(*m*-tolylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

2-(Pyrrolidin-2-ylmethylamino)-4-(*m*-tolylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

2-(3-Aminopyrrolidin-1-yl)-4-(*m*-tolylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

2-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1,5-dimethyl-1*H*-pyrazol-4-yl)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

2-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1*H*-indol-2-yl)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

2-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1*H*-pyrazol-5-yl)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

2-(3-Aminopropyl)-4-(*m*-tolylamino)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(benzofuran-3-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-aminocyclohexylamino)-7-fluoro-4-(imidazo[1,2-*a*]pyridin-3-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-aminocyclohexylamino)-4-(benzo[*b*]thiophen-3-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*S*,2*R*)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(*2H*)-one;

(*R*)-6-(2-Amino-3-ethoxypropylamino)-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*R*)-6-(2-Amino-3-ethoxypropylamino)-7-fluoro-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-(2-Amino-3,3,3-trifluoropropylamino)-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*R*)-4-Methyl-2-(3-oxo-4-(*m*-tolylamino)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)pentanamide;

6-(*cis*-4-Aminotetrahydrofuran-3-ylamino)-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2H)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1-ethyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1-ethyl-1*H*-pyrazol-4-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1-cyclopropyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1-(difluoromethyl)-1*H*-pyrazol-4-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1-cyclopropyl-1*H*-pyrazol-4-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

cis-6-(2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-7-fluoro-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-(*cis*-2-Amino-4,4-difluorocyclopentylamino)-7-fluoro-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-c]pyridin-3(2*H*)-one;

6-(*cis*-2-Amino-3,3-difluorocyclohexylamino)-7-fluoro-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-(*cis*-2-Amino-3,3-difluorocyclohexylamino)-4-(1-(difluoromethyl)-1*H*-pyrazol-4-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-(*cis*-2-amino-3,3-difluorocyclohexylamino)-4-(1-cyclopropyl-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;

(*R*)-2-(7-Fluoro-4-(1-methyl-1*H*-pyrazol-4-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(4-(1-(Difluoromethyl)-1*H*-pyrazol-4-yl)-7-fluoro-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(4-(1-Cyclopropyl-1*H*-pyrazol-4-yl)-7-fluoro-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(4-(Benzofuran-3-yl)-7-fluoro-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(7-Fluoro-3-oxo-4-(pyrazolo[1,5-*a*]pyridin-3-yl)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-chloro-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-3-oxo-4-(*m*-tolylamino)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridine-7-carbonitrile;

(*R*)-6-(2-Amino-3-methoxypropylamino)-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*R*)-6-(2-Amino-3-methoxypropylamino)-3-oxo-4-(*m*-tolylamino)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridine-7-carbonitrile;

(*R*)-6-(2-Amino-3-methoxypropylamino)-7-fluoro-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

7-Acryloyl-6-((1*R*,2*S*)-2-aminocyclohexylamino)-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-iodo-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-(1*H*-pyrazol-4-yl)-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-(*cis*-2-Amino-3,3-difluorocyclohexylamino)-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-(1-methyl-1*H*-pyrazol-5-yl)-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-4-Aminotetrahydro-2*H*-pyran-3-ylamino)-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

tert-Butyl (1*S*,2*R*)-2-(3-oxo-7-phenyl-4-(*m*-tolylamino)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)cyclohexylcarbamate;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-methyl-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-7-fluoro-4-(*m*-tolylamino)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-methyl-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*R*)-6-(2-Amino-3-methoxypropylamino)-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-7-fluoro-4-(pyrazolo[1,5-*a*]pyridin-3-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-4-(1-(difluoromethyl)-1*H*-pyrazol-4-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-4-(benzofuran-3-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*S*)-6-(3-Aminopyrrolidin-1-yl)-7-fluoro-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*S*)-6-(3-Aminopiperidin-1-yl)-7-fluoro-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(1-isopropyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

7-Fluoro-4,6-bis(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-bromo-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

2-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(1-(4-fluorophenyl)-1*H*-pyrazol-4-yl)-6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidin-5-one;

(*R*)-6-(2-Amino-3-methoxypropylamino)-7-fluoro-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-7-fluoro-4-(thiophen-3-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-7-fluoro-4-(4-methylthiophen-2-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(4-methylthiophen-2-yl)-1*H*-pyrrolo[3,4-c]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(thiophen-3-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*R*)-2-(7-Fluoro-4-(1-methyl-1*H*-pyrazol-4-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-*N*,4-dimethylpentanamide;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(5-methylthiophen-2-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*R*)-2-(7-Fluoro-4-(4-methylthiophen-2-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(7-Fluoro-3-oxo-4-(thiophen-3-yl)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(7-Fluoro-4-(5-methylthiophen-2-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-4-(2-aminothiazol-5-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*R*)-2-(7-Fluoro-4-(furan-2-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(7-Fluoro-4-(furan-3-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(7-Fluoro-4-(furan-2-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(4-(5-Cyanothiophen-2-yl)-7-fluoro-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(4-(4-Cyanothiophen-2-yl)-7-fluoro-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(7-Fluoro-3-oxo-4-(thiazol-5-yl)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

(*R*)-2-(7-Fluoro-4-(isothiazol-5-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-1,1-dimethyl-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1*H*-pyrazol-3-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(2-methylthiazol-5-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-7-fluoro-4-(5-methylthiophen-2-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-1-methyl-4-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*R*)-2-(7-Fluoro-3-oxo-4-(thiophen-2-yl)-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-7-fluoro-4-(thiophen-2-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-7-fluoro-4-(thiazol-5-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(thiophen-2-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-7-fluoro-4-(4-(trifluoromethyl)-1*H*-imidazol-1-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((1*R*,2*S*)-2-Aminocyclohexylamino)-7-fluoro-4-(4-methyl-1*H*-imidazol-1-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-7-fluoro-4-(3-methylisothiazol-5-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-7-fluoro-4-(2-methylthiazol-5-yl)-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

(*R*)-2-(7-Fluoro-4-(2-methylthiazol-5-yl)-3-oxo-2,3-dihydro-1*H*-pyrrolo[3,4-*c*]pyridin-6-ylamino)-4-methylpentanamide;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-4-(5-chlorothiophen-2-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

6-((3*R*,4*R*)-3-Aminotetrahydro-2*H*-pyran-4-ylamino)-4-(1-cyclopropyl-1*H*-pyrazol-4-yl)-7-fluoro-1*H*-pyrrolo[3,4-*c*]pyridin-3(2*H*)-one;

a stereoisomer of any of the aforementioned compounds; and

a pharmaceutically acceptable salt of any of the aforementioned compounds or stereoisomers.

33. A pharmaceutical composition comprising:

a compound or pharmaceutically acceptable salt as defined in any one of claims 1 to 32; and

a pharmaceutically acceptable excipient.

34. A use of a compound or pharmaceutically acceptable salt as defined in any one of claims 1 to 32, as a medicament.

35. A use of a compound or pharmaceutically acceptable salt as defined in any one of claims 1 to 32, for the manufacture of a medicament for the treatment of a disease or condition for which a SYK inhibitor is indicated.

36. A method of treating a disease or condition in a subject for which a SYK inhibitor is indicated, the method comprising administering to the subject an effective amount of a compound or pharmaceutically acceptable salt as defined in any one of claims 1 to 32.

37. A method of treating a disease or condition in a subject, the method comprising administering to the subject an effective amount of a compound or pharmaceutically acceptable salt as defined in any one of claims 1 to 32, wherein the disease or condition is selected from allergic rhinitis, allergic asthma, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, psoriasis, immune thrombocytopenic purpura, inflammatory bowel disease, chronic obstructive pulmonary disease, and thrombosis.

38. A method of treating a disease or condition in a subject, the method comprising administering to the subject an effective amount of a compound or pharmaceutically acceptable salt as defined in any one of claims 1 to 32, wherein the disease or condition is selected from a hematological malignancy and an epithelial cancer.

39. A method according to claim 38, wherein the hematological malignancy is selected from acute myeloid leukemia, B-cell chronic lymphocytic leukemia, B-cell lymphoma, and T-cell lymphoma.

40. A method according to claim 38, wherein the epithelial cancer is selected from lung cancer, pancreatic cancer, and colon cancer.

41. A combination of an effective amount of a compound or pharmaceutically acceptable salt as defined in any one of claims 1 to 32, and at least one additional pharmacologically active agent.

42. A combination according to claim 41, wherein the additional pharmacologically active agent is a DMARD.

43. A combination according to claim 42, wherein the DMARD is methotrexate.